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Abstract
Background & Aims—The extent of HBV infection to infants of HBV/HIV-coinfected 
pregnant women in sub-Saharan Africa is unknown. The aim of this study was to assess 
prevalence of HBV infection among antiretroviral-naïve, HIV-infected pregnant women in 
Malawi and examine HBV transmission to their infants.
Methods—Plasma from 2048 HIV-infected, Malawian women and their infants were tested for 
markers of HBV infection. Study participants were provided standard-of-care health services, 
which included administration of pentavalent vaccine to infants at 6, 10, and 14 weeks of age.
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Results—One-hundred and three women (5%) were HBsAg-positive; 70 of these HBsAg-
positive women were also HBV-DNA-positive. Sixteen women (0.8%) were HBV-DNA-positive 
but HBsAg-negative. Five of 51 infants (9.8%) born to HBsAg-positive and/or HBV-DNA-
positive women were HBV-DNA-positive by 48 weeks of age. HBV DNA concentrations of two 
infants of mothers who received extended lamivudine-containing anti-HIV prophylaxis were <4 
log10 IU/ml compared to ≥8 log10 IU/ml in three infants of mothers who did not.
Conclusions—HBV DNA was detected in nearly 10% of infants born to HBV/HIV-coinfected 
women. Antenatal testing for HIV and HBV, if instituted, can facilitate implementation of 
prophylactic measures against infant infection by both viruses. Published by Elsevier B.V. on 
behalf of the European Association for the Study of the Liver.
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Introduction
Hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV) are among the 
leading causes of infectious disease deaths worldwide [1]. These viruses are highly endemic 
in sub-Saharan Africa, where infection with both viruses is frequent [2]. Pregnant women 
who are co-infected with HIV and HBV tend to be highly viremic for HBV [3] and may be 
at heightened risk of HBV transmission to their infants [4,5]. HBV infection among children 
in sub-Saharan Africa, in contrast to East Asia [6], has tended to be acquired during later 
infancy and early childhood, rather than perinatally [7,8]. HBV can be found in many body 
fluids including, blood, breast milk, saliva, sweat, tears, and urine [9,10]. However, several 
epidemiologic studies outside of Africa have shown no increased HBV transmission in 
breastfeeding infants compared to non-breastfeeding infants who receive appropriate anti-
HBV prophylaxis [9,11,12].
Before vaccination against hepatitis B was introduced, seropositivity for hepatitis B surface 
antigen (HBsAg) could be detected in up to one-third of African children younger than 5 
years old [7,13–15]. Acquiring hepatitis B in early childhood carries a high risk of 
progressing to chronic hepatitis B [16], which may progress to chronic liver disease, 
including hepatocellular carcinoma, in later life [17]. This risk may be even higher among 
those HIV-coinfected [18]. Although almost all African countries have implemented 
childhood vaccination against hepatitis B [19], the degree to which vaccination protects 
against HBV infection in infants born to HIV/HBV-coinfected women is not known.
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study, conducted in Lilongwe, 
Malawi, [20,21] provided an opportunity to determine the extent of HBV infection among 
HIV-infected pregnant women and to examine the risk of HBV transmission to their infants.
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Study population and design
The BAN study screened 3572 antiretroviral-naive, HIV-infected pregnant women attending 
3 antenatal clinics in Lilongwe and enrolled 2369 women who met antenatal and postnatal 
eligibility criteria between March 2004 and February 2009 (www.thebanstudy.org; 
www.ClinicalTrials.gov number NCT00164736) [20–22]. This study was a randomized, 
controlled, clinical trial to investigate antiretroviral prevention of mother-to-child 
transmission of HIV-1 during breastfeeding. Eligibility for BAN was determined using 
antenatal criteria (women ≥14 years of age, ≤30 weeks gestation, and with no serious 
complications of pregnancy, no prior antiretroviral use, CD4+ count ≥200 cells/μl, 
hemoglobin ≥7 g/dl and plasma alanine aminotransferase (ALT) level ≤2.5 times the upper 
limit of normal) and postnatal criteria (infants of birth weight ≥2000 g, no infant or maternal 
condition precluding study interventions, and women having accepted perinatal 
antiretroviral regimen and received treatment assignment within 36 h of delivery). All 
mothers in labor and their newborn infants received a single dose of oral nevirapine and 7 
days of prophylaxis as Combivir (zidovudine, 300 mg, plus lamivudine, 150 mg) twice-daily 
from the onset of labor for the mothers and zidovudine (2 mg per kilogram of body weight) 
and lamivudine (4 mg per kilogram) twice-daily for the infants. Mother-infant pairs were 
randomly assigned to 3 antiretroviral intervention arms: (1) no further antiretroviral 
prophylaxis; (2) 28 weeks of infant nevirapine; and (3) 28 weeks of maternal antiretrovirals. 
Babies randomized to the infant nevirapine arm received a daily dose of nevirapine that 
increased according to age, ranging from 10 mg daily in the first 2 weeks to 30 mg daily for 
weeks 19 through 28. Mothers on the maternal antiretroviral arm received Combivir (twice 
daily) and either nevirapine (200 mg) once-daily for 14 days and twice-daily through week 
28 (n = 39), nelfinavir (1250 mg) twice-daily through week 28 (n = 146), or Kaletra 
(lopinavir, 400 mg, plus ritonavir, 100 mg) twice-daily through week 28 (n = 664). These 
changes in the maternal antiretroviral regimen were made for reasons of safety, availability, 
and potency [21]. Antiretroviral adherence reports were taken at five follow-up visits, and 
mothers reported taking all their antiretroviral doses a mean of 89% of the time and giving 
all infant antiretroviral doses 94% of the time. All mother-infant pairs were escorted after 
their 6-week study visit to the onsite Under 5 Clinic for initiation of the Quinvaxem 
(Novartis Vaccines & Diagnostics) pentavalent vaccine series against diphtheria, tetanus, 
pertussis, hepatitis B recombinant and Haemophilus influenza type b (Hib) per standard of 
care. At subsequent BAN study visits, mothers were reminded to return to the Under 5 
Clinic for their infants’ immunizations scheduled at 10 and 14 weeks of age. Hepatitis B 
immunoglobulin was not available in Malawi during the study period. Infants who tested 
HIV positive during the first two weeks postpartum or during BAN study follow-up were 
disenrolled and referred for care. The BAN study and the current viral hepatitis substudy 
were approved by the Malawi National Health Science Research Committee and 
institutional review boards at the University of North Carolina at Chapel Hill and the U.S. 
Centers for Disease Control and Prevention (CDC). All women provided written, informed 
consent for specimen storage and laboratory studies.
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In March 2008, the current study began analyzing stored plasma specimens collected from 
women in their second and third trimester of pregnancy at pre-randomization eligibility 
screening through November 2007. Throughout the study, plasma specimens were shipped 
from −80 °C storage in Lilongwe to a repository at CDC in Atlanta. Available maternal 
plasma specimens (n = 2048) were transferred from the repository to CDC’s Division of 
Viral Hepatitis. Specimens were tested first for total antibody to hepatitis B core antigen 
(anti-HBc), and those anti-HBc-positive were assayed for HBsAg using the Vitros 
Chemiluminescence Immunoassay (Ortho Clinical Diagnostics, Rochester, NY). Specimens 
found HBsAg-positive were tested for hepatitis B e antigen (HBeAg) using the ETI-EBK 
PLUS assay (Diasorin Inc., Stillwater, MN). Specimens found HBsAg-positive underwent 
HBV DNA quantification using the COBAS TaqMan HBV Test (Roche Molecular, 
Indianapolis, IN) calibrated for quantifying 200 μl volumes by using the WHO International 
Standard for HBV DNA NAT assays, code 97/746. Maternal anti-HBc-positive specimens 
that were HBsAg-negative were tested for HBV DNA with an in-house assay based on 
reverse-transcription polymerase chain reaction [23]. Using serial dilutions of the WHO 
standard, code 97/746, it was determined that the lower limit of detection for the modified 
COBAS assay and the in-house assay was 1.5 log10 IU/ml of HBV DNA. Testing for 
hepatitis B infection in infants was limited to infants of mothers who were HBsAg-positive 
or HBV-DNA-positive at the screening visit and enrolled in BAN at delivery. Also, the 
analysis was limited to HIV-uninfected infants because the BAN study disenrolled infants 
who were HIV-infected in utero (as indicated by a positive HIV RNA test by 2 weeks of 
life) or who became HIV-infected during follow-up and therefore, specimen availability on 
HIV-infected infants is minimal. All available plasma samples taken at 2 weeks (n = 57) 
and/or 48 weeks (n = 51) from 72 HIV-uninfected infants born to HBsAg-positive or 
HBsAg-negative/HBV-DNA-positive mothers were assayed for HBV DNA using the 
COBAS TaqMan HBV Test calibrated for quantifying 200 μl volumes. For infants who 
were HBV-DNA-positive at 48 weeks and either HBV-DNA-negative or not tested at 2 
weeks, samples from 12 and 24 weeks were also tested for HBV DNA. One infant (Infant E, 
see below) with a low HBV concentration first detected at 48 weeks was retested for HBV 
DNA on a separate aliquot to confirm that it was not falsely positive. Samples with 
sufficient volumes from infants found HBV-DNA-positive at 48 weeks, along with those 
from their mothers, were processed for nucleotide sequencing of the S gene of HBV to 
determine genotype and identify single-nucleotide polymorphisms associated with vaccine 
escape [24,25].
Statistical analysis
HBV prevalence estimates among the mothers and infants were derived with 95% 
confidence intervals based on the binomial exact method. Wilcoxon-Mann-Whitney tests 
were used to compare the maternal HBV DNA load by maternal HBeAg status, and exact 
Wilcoxon-Mann-Whitney tests were used to compare maternal CD4 count and HBV DNA 
load by infant HBV status at 48 weeks. The Fisher’s Exact test was used to evaluate an 
association between maternal extended lamivudine-containing prophylaxis and infant HBV 
status at 48 weeks. Results were considered statistically significant if the p value was <0.05. 
All statistical analyses were performed using SAS, version 9.2.
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The median age at antenatal screening of the enrolled 2048 women was 25 (interquartile 
range [IQR], 22–29) years. The median CD4+ T cell count was 440 (IQR, 333–581) 
cells/mm3 and ALT level was 13 (IQR, 11–16) IU/L. Among the women, 989 (48.3%) 
tested anti-HBc-positive (Fig. 1), and of those, 103 tested HBsAg-positive, giving an overall 
HBsAg detection proportion of 5% (95% confidence interval [CI], 4.2–6.1%). Of the 
HBsAg-positive women, 70/103 (68%) were HBV-DNA-positive and 39/102 (38.2%) were 
HBeAg-positive (Fig. 1). Sample volume was sufficient for measuring HBV DNA 
concentration of 69 women, the median being 4.2 (IQR, 1.5–8.9) log10 IU/ml. The median 
was significantly higher in samples from 35 HBeAg-positive women (7 log10 IU/ml) 
compared to those from 33 HBeAg-negative women whose concentration could be 
measured (2.7 log10 IU/ml) (p <0.001). HBV DNA was detected in 16 samples from women 
who were anti-HBc-positive and HBsAg-negative. For the purpose of the current study these 
women were considered to have occult HBV infection, and the estimated prevalence of 
occult infection was therefore 0.8% (95% CI, 0.5–1.3%).
Infant characteristics
Of the 72 infants tested at 2 weeks (n = 57) and/or 48 weeks (n = 51), five were HBV-DNA-
positive (Table 1). All HBV-DNA-positive infants were born to HBeAg-positive mothers. 
The proportion of infants HBV-DNA-positive at 48 weeks by maternal HBV marker status 
was 33% (5/15) for HBeAg-positive and HBV-DNA-positive mothers, 12.8% (5/39) for 
HBV-DNA-positive mothers, 11.9% (5/42) for HBsAg-positive mothers, and 9.8% (5/51) 
for HBsAg-positive or HBV-DNA-positive mothers (Table 1). The proportion of infants 
HBV-DNA-positive at 48 weeks by study antiretroviral intervention arm was 2 of 20 
mother-infant pairs on the maternal lamivudine-containing regimen, 1 of 13 on the infant-
nevirapine regimen, and 2 of 18 on the control arm. The difference in HBV-DNA-positivity 
at 48 weeks of infants born to HBsAg-positive mothers who received extended prophylaxis 
compared to those born to HBsAg-positive mothers who did not was insignificant (2/16 
[12.5%] vs. 3/26 [11.5%]). There was no statistically significant difference in the median 
CD4+ cell count of the 5 mothers of HBV-DNA-positive infants (651 cells/mm3) compared 
to 37 HBsAg-positive mothers of HBV-DNA-negative infants (441 cells/mm3). The median 
HBV DNA concentration was significantly higher in the 5 mothers of HBV-DNA-positive 
infants (8 log10 IU/ml) compared to that in 24 HBsAg-positive mothers with quantifiable 
HBV DNA and HBV-DNA-negative infants (3.9 log10 IU/ml) (p = 0.001). Four of the 5 
mothers of HBV-DNA-positive infants had HBV DNA concentrations >7.5 log10 IU/ml 
(Table 2). Two infants (Infants B and C) had sufficient specimen quantity for HBV 
subgenomic sequencing and were determined to be infected with HBV belonging to 
subgenotype A1; sequencing of HBV from the corresponding mothers showed complete 
infant-mother identity. No nucleotide sequence polymorphisms that would confer immune-
escape properties were observed.
Chasela et al. Page 5













Time of infant HBV infection
Of the five HBV-DNA-positive infants, HBV DNA was detected in one (Infant A) at 2 and 
48 weeks (samples at 12 and 24 weeks were not tested); in two (Infants B and C) at 12, 24, 
and 48 weeks, but not at 2 weeks; in one (Infant D) at 12 and 48 weeks, but not at 24 weeks 
(sample at 2 weeks was not tested); and in one (Infant E) at 48 weeks but not the earlier 
weeks (Table 2). To exclude the possibility that HBV DNA first measured in Infant E’s 
sample at week 48 weeks reflected false-positivity, the concentration of HBV DNA in 
another aliquot of that sample was measured; the value presented in Table 2 for Infant E 
reflects the average of values obtained from the two measurements. When examining the 
time of HBV DNA positivity according to the three antiretroviral intervention arms of the 
BAN study, Infants D and E, who were born to mothers who received 28 weeks of 
lamivudine-containing prophylaxis postpartum in addition to prophylaxis given during labor 
and one week after delivery, had HBV DNA concentrations of <4 log10 IU/ml at 48 weeks; 
these levels were lower compared to the ≥8 log10 IU/ml in Infants A–C whose mothers did 
not receive extended lamivudine-containing prophylaxis (Table 2). Infant E was included in 
a BAN substudy of antiretrovirals pharmacokinetics, and it was determined that the 
concentrations of lamivudine in breast milk (1930 ng/ml at 6 weeks, 1410 ng/ml at 12 
weeks, and 898 ng/ml at 24 weeks) were about twice that in maternal plasma (1366, 765, 
and 327 ng/ml, respectively). Lamivudine was detectable at low levels in the infant’s plasma 
(53, 23, and 12 ng/ml at 6, 12, and 24 weeks, respectively.
Infants of women with occult HBV infection
None of the infants of mothers with occult HBV infection were HBV-DNA-positive. When 
mothers with occult HBV infection are taken into consideration, the prevalence of HBV 
infection in infants born to all HBV-infected mothers (5/51) is 9.8%.
Discussion
The BAN study, conducted in Malawi, provided the setting for one of the largest 
descriptions of HBV infection among HIV-infected, pregnant women in sub-Saharan Africa 
and allowed for the extent of HBV infection in their infants to be determined. Of the 2048 
women tested, almost half (48.3%) were anti-HBc-positive, indicating that a substantial 
proportion had prior HBV infection. The proportion of HBsAg-positivity, signifying active 
HBV infection, was 5%. It is of the same magnitude as the 4% determined from a study in 
Uganda and Rwanda of 247 HIV-infected, pregnant women [26], but lower than the 8%–
36% estimated from smaller studies of HIV-infected, pregnant women in other African 
countries [27–31]. Of the HBsAg-positive women in our study, 68% were HBV-DNA-
positive, which is similar to the 71% observed in Uganda and Rwanda [26], but higher than 
the 27% observed in Cote d’Ivoire [31]. The 38% HBeAg positivity among HBsAg-positive 
women in our study is similar to the 33% found in HIV-infected, pregnant women in 
Uganda and Rwanda [26], but higher than the 0% to 22% reported from smaller studies of 
HIV-infected, pregnant women from Cameroon and Cote d’Ivoire [30,31]. The prevalence 
of occult HBV infection in this study was 0.8%, which contrasts with the 10%–20% 
observed in HIV-infected patients in South Africa [32–34] and Cote D’Ivoire [35]. Although 
variations across studies in the detection of these various HBV serological markers may 
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reflect differences in the size, demography and stage of HIV disease of the study populations 
and the genotypic distribution of endemic HBV strains, the usage of assays with disparate 
performance characteristics likely contributed. As expected and consistent with the findings 
from elsewhere [26,28], women positive for HBeAg had significantly higher HBV DNA 
concentrations compared to those who were negative.
We found that 11.9% of infants born to HBsAg-positive women were positive for HBV 
DNA at 48 weeks of age. Maternal HBeAg status was the most significant predictor of 
infant HBV infection, which is expected since HBeAg-positive women tend to be highly 
viremic and therefore highly infectious. Non-immunized infants born to HBeAg-positive, 
HBsAg-positive mothers have a higher probability of HBV transmission of 70–90% 
compared to <10% probability of transmission for non-immunized infants of HBeAg-
negative, HBsAg-positive mothers [36]. All 5 HBV-DNA-positive infants in this study were 
born to HBeAg-positive mothers, four of whom had HBV DNA concentrations >7.5 log10 
IU/ml. The routes along which HBV may be transmitted from mother to infant are 
transplacental, perinatal and post-natal [37–39]. Body fluids from which HBV could be 
transmitted postnatally include breast milk, blood, saliva, sweat, tears and urine [9,10]. 
Postnatal transmission from other members of the household cannot be excluded [40,41]; 
however, the fact that all infants in our study were born to HBeAg-positive women with 
high HBV DNA concentration argues in favour of transmission from their mothers. For 
Infants B and C, the particularly high viremia of their mothers and the complete mother-
infant identity in the HBV S gene further suggest that transmission was maternal.
Of the four infants (A, B, C, and E) tested at two and 48 weeks, one infant (A) first tested 
HBV-DNA-positive at 2 weeks, 2 infants (B and C) at 12 weeks, and the remaining infant 
(E) at 48 weeks. Whereas positivity at 2 weeks in Infant A may reflect transplacental, 
perinatal, or early post-natal HBV infection, positivity from 12 weeks in infants B and C 
reflects perinatal or post-natal infection. The infections in infants D and E despite maternal 
prophylaxis with lamivudine-containing antiretrovirals could be due to resistance mutations, 
but there was insufficient specimen volume to sequence the viral genomes. Alternatively, 
the relatively low HBV DNA concentrations in infants D and E whose mothers received 28 
weeks of lamivudine-containing antiretroviral prophylaxis suggest that lamivudine 
prophylaxis given to mothers during breastfeeding could have suppressed HBV replication 
in their infants. One of these infants (Infant E) was tested for lamivudine in plasma and was 
determined to have detectable lamivudine at 6, 12, and 24 weeks when the infant was HBV-
negative. These observations are based on a relatively small sample set, however. Further 
investigations are needed to confirm that lamivudine in breast milk plays a role against HBV 
in the infant, particularly in view of reports stating that lamivudine can attain a higher 
concentration in breast milk compared to plasma, and breastfeeding infants exposed to it 
may carry low but detectable levels of lamivudine in their plasma [42].
The current study had some limitations. First, our testing algorithm did not include testing 
for HBsAg and HBV DNA in anti-HBc-negative women; nonetheless, the likelihood of 
losing anti-HBc antibody is small and more typically encountered during severe 
immunosuppression [43]. Second, the blood volume from study infants was not sufficient 
for HBsAg testing, and infant blood was tested only for HBV DNA as marker of active 
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HBV infection. Third, the infants in this study were born to mothers who met the eligibility 
criteria for randomization to a BAN postnatal intervention, which included serum ALT level 
≤2.5 times the upper limit of normal and a CD4+ cell count ≥200 cells/ll. However, only two 
pregnant women with abnormally high ALT activities were excluded from the study. The 
BAN study also excluded infants with documented HIV infection at 2 weeks (implying in 
utero infection). Therefore, the infants in this study may not fully represent the general 
population of infants born to HIV-infected pregnant women and could present an 
underestimate of the true HBV transmission in this population. Another limitation is 
associated with the administration of the pentavalent vaccine as per standard of care in an 
onsite immunization clinic and not as part of the BAN study, in the course of which 
vaccination records were not linked to the BAN study. Nonetheless, the 5 infants who 
became HBV positive could be considered to have been vaccinated, particularly as all 5 
infants were recorded to have been brought by their mothers to attend the 6-, 12-, and 48-
week visits. Finally, based on the BAN study design, all women and infants were given 
lamivudine (along with zidovudine) for 7 days after delivery. Although the exposure of the 
infants to lamivudine was short, the possibility that this anti-HBV drug [1] may have 
interrupted perinatal transmission or suppressed HBV replication during the first week of 
life, thereby mitigating infection or delaying detection of HBV infection in the infants, 
cannot be ruled out.
In summary, among 2048 HIV-infected, pregnant women studied in Malawi, 5% and 4.2% 
were seropositive for HBsAg and HBV DNA, respectively. Among the HBsAg-seropositive 
and HBV-DNA-seropositive mothers, HBV infection in infants was observed in 11.9% and 
12.8%, respectively. Given the high endemicity of HIV and HBV infection in sub-Saharan 
Africa, and the fact that HBV infection early in life carries a high risk for developing 
chronic hepatitis B later in life, it is recommended that efficient strategies are implemented 
to prevent HBV infection during infancy. Currently, the WHO recommends that all infants 
should receive their first dose of hepatitis B vaccine as soon as possible after birth, 
preferably within 24 h [44]. The logistical challenges of delivering the birth dose in certain 
resource-limited settings need consideration, however [45]. Similar considerations pertain to 
passive immunoprophylaxis, which is recommended, along with vaccination, for infants of 
HBsAg-positive mothers, particularly those who also are HBeAg-seropositive [44]. 
Administration of antivirals during pregnancy is another promising approach to prophylaxis 
against infant HBV infection [1,42], particularly for highly viremic women. Nonetheless, the 
cost and feasibility of viral load testing before and after antiviral therapy require 
consideration. Since the BAN Study, the Malawi Ministry of Health has implemented 
Option B+, in which all HIV-infected pregnant and breastfeeding women are eligible for 
lifelong antiretroviral therapy regardless of CD4 count. The regimen of choice is tenofovir, 
lamivudine, and efavirenz, two of which (tenofovir and lamivudine) are active against HBV. 
Implementation of Option B+ would be expected to further reduce HBV transmission but, in 
light of our study’s results, further research should be performed to assess its true impact. 
Currently, there is no routine antenatal screening for HBV infection in sub-Saharan Africa. 
Ideally, HBV testing should be integrated with the antenatal HIV testing so that pregnant 
women may be given care appropriate to their coinfected state and their infants receive 
timely and complete prophylaxis against infection by both viruses.
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Fig. 1. Flowchart of HBV testing on 2048 HIV-infected, pregnant women screened for the 
Breastfeeding, Antiretrovirals, and Nutrition study
aInfant testing for hepatitis B was limited to infants born to HBsAg-positive (n = 103) or 
HBsAg-negative and HBV-DNA-positive (n = 16) mothers at the screening visit who 
enrolled in BAN at delivery (n = 95) and whose infants remained HIV-negative at 2 weeks 
of life (n = 79) and had plasma specimens available for HBV testing at 2 weeks (n = 57) 
and/or 48 weeks (n = 51) of age for a total of 72 infants tested for hepatitis B. These infants 
were included in the analysis of HBV infection among infants (Table 1). bVolume 
insufficient for HBeAg testing of one mother and for determining HBV DNA concentration 
in another mother.
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Table 1
Infant HBV DNA serostatus at 2 and 48 weeks of age according to maternal antenatal HBV serostatus.
Maternal antenatal HBV serostatus No. positive/No. tested
At 2 wk At 48 wk
HBsAg-positive/HBeAg-positive/HBV DNA-positive 1/16 (6.3%) 5/15 (33.3%)
HBsAg-positive/HBeAg-negative/HBV DNA-positive 0/18 0/15
HBsAg-positive/HBV DNA-negative 0/21a 0/12a
HBsAg-negative/HBV DNA-positive 0/2 0/9
Total No. of infant samples testedb 57 51
a
Includes, in denominators, 6 HBeAg-positive, 26 HBeAg-negative, and 1 HBeAg not tested.
b
Samples were available from 72 infants for testing at 2 and/or 48 weeks: 36 infants were tested at both time points, 21 were tested only at 2 
weeks, and 15 were tested only at 48 weeks.
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